Document:

Securities Purchase Agreement

 Exhibit 10.1 
 SECURITIES PURCHASE AGREEMENT 
 THIS SECURITIES PURCHASE AGREEMENT
(this “Agreement”) is made as of the 23rd day of August, 2011 by and between InfoSpace, Inc., a Delaware corporation (the “Company”), and Cambridge Information Group I LLC, a Delaware limited liability company (the
“Investor”). 
 Recitals 
 A. The Investor wishes to purchase from the Company, and the Company wishes to sell and issue to the Investor, upon the terms and conditions stated in this Agreement, 764,192 shares (the
“Shares”) of the Company’s Common Stock, par value $0.0001 per share (and any securities into which the Common Stock may be reclassified, the “Common Stock”), and a warrant to purchase an aggregate of 1,000,000
shares of Common Stock in the form attached hereto as Exhibit A (the “Warrant”); and 
 B.
Contemporaneous with the sale of the Shares and the Warrant, the parties hereto will execute and deliver a Stockholder Agreement, in the form attached hereto as Exhibit B (the “Stockholder Agreement”). 

In consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the parties hereto agree as follows: 
 1. Definitions. In addition to those terms defined
above and elsewhere in this Agreement, for the purposes of this Agreement, the following terms shall have the meanings here set forth: 
 “Affiliate” means, with respect to any Person, any other Person which directly or indirectly Controls, is Controlled by, or is under common Control with, such Person. 

“Bylaws” means the Restated Bylaws, as amended, of the Company. 

“Certificate of Incorporation” means the Amended and Restated Certificate of Incorporation, as amended, of the Company.

 “Company’s Knowledge” means the actual knowledge of the Company’s Chief Executive Officer, Chief
Financial Officer and General Counsel, after reasonable inquiry. 
 “Confidential Information” means trade
secrets, confidential information and know-how (including but not limited to ideas, formulae, compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications, support
documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related information). 

 “Control” means the possession, direct or indirect, of the power to direct
or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 
 “Intellectual Property” means all of the following: (i) patents, patent applications, patent disclosures and inventions (whether or not patentable and whether or not reduced to
practice); (ii) trademarks, service marks, trade dress, trade names, corporate names, logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing; (iii) copyrights and copyrightable works;
(iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary computer software (including but not limited to data, databases and documentation). 

“Material Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations,
condition (financial or otherwise), business or prospects of the Company and the Subsidiary taken as a whole, or (ii) the ability of the Company to issue and sell the Securities and to perform its obligations under the Transaction Documents.

 “Material Contract” means the contracts to which the Company and/or the Subsidiary is a party which are
listed as exhibits to any of the SEC Filings. 
 “Nasdaq” means The Nasdaq Global Select Market. 

“Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association,
joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 
 “Purchase Price” means $7,000,000. 

“Securities” means the Shares, the Warrant and the Warrant Shares. 

“Subsidiary” means InfoSpace Sales LLC, a Delaware limited liability company. 

“Transaction Documents” means this Agreement, the Warrant and the Stockholder Agreement. 

“Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrant. 

2. Purchase and Sale of the Shares and Warrant. Subject to the terms and conditions of this Agreement, on the date hereof
(the “Closing Date”), the Investor shall purchase, and the Company shall sell and issue to the Investor, the Shares and Warrant in exchange for the Purchase Price. Upon receipt by the Company of the amount of the Purchase Price and
the Investor Deliverables (as defined below) as provided in Section 3, the certificate evidencing the Shares and the Warrant shall be released to the Investor (the “Closing”). The Closing shall take place at the offices
of Perkins Coie LLP, 1201 Third Avenue, Suite 4800, Seattle, Washington 98101, or at such other location and on such other date as the Company and the Investor shall mutually agree. 

  
 -2-

 3. Closing Deliveries.

3.1 Investor. On the Closing Date, the Investor shall deliver or cause to be delivered to the Company each of the following (the
“Investor Deliverables”): 
 (a) the Purchase Price, by wire transfer of immediately available funds to the
account of the Company as instructed in writing by the Company; and 
 (b) the Stockholder Agreement, duly executed by the
Investor. 
 3.2 Company. On the Closing Date, the Company shall deliver or cause to be delivered to the Investor each of
the following: 
 (a) evidence of issuance of 764,192 shares of Common Stock in book entry form, registered in the name of the
Investor, upon payment of the Purchase Price to the Company; 
 (b) the Warrant, duly executed by the Company; and 

(c) the Stockholder Agreement, duly executed by the Company. 
 4. Representations and Warranties of the Company. The Company hereby represents and warrants to the Investor that, except as set forth in the schedules delivered herewith (collectively, the
“Disclosure Schedules”): 
 4.1 Organization, Good Standing and Qualification. The Company and the
Subsidiary are each (a) duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), and (b) has all requisite corporate power and
authority to carry on its business as now conducted and to own its properties. Each of the Company and the Subsidiary is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of
its business or its ownership or leasing of property makes such qualification necessary unless the failure to so qualify has not and could not reasonably be expected to have a Material Adverse Effect.

4.2 Authorization. The Company has all requisite corporate power and authority to execute and deliver this Agreement and
consummate the transactions contemplated hereby and under the other Transaction Documents. The Company has taken all requisite action on the part of the Company, its officers, directors and stockholders necessary for (a) the authorization,
execution and delivery of the Transaction Documents, (b) authorization of the performance of all obligations of the Company under the Transaction Documents, and (c) the authorization, issuance (or reservation for issuance) and delivery of
the Securities. The Transaction Documents constitute the legal, valid and binding obligations of the Company, 

  
 -3-

 
enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability,
relating to or affecting creditors’ rights generally. 
 4.3 Capitalization. Schedule 4.3 sets forth, as
of the date hereof, (a) the authorized capital stock of the Company, (b) the number of shares of capital stock issued and outstanding, (c) the number of shares of capital stock issuable pursuant to the Company’s stock plans and
(d) the number of shares of capital stock issuable and reserved for issuance pursuant to securities (other than the Shares and the Warrant) exercisable for, or convertible into or exchangeable for any shares of capital stock of the
Company. All of the issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued and are fully paid, nonassessable and were issued in full compliance with applicable law and any rights of third
parties. The Company owns all of the outstanding equity interests of the Subsidiary, free and clear of any lien, encumbrance or other adverse claim. No Person is entitled to pre-emptive or similar statutory or contractual rights with respect to
any securities of the Company or the Subsidiary. Except as contemplated by this Agreement or as disclosed on Schedule 4.3, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of
any character under which the Company or the Subsidiary is or may be obligated to issue any equity securities of any kind. The issue and sale of the Shares and Warrant will not, immediately or with the passage of time, obligate the Company to
issues shares of Common Stock or other securities to any Person (other than the Investor) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under such securities.

 4.4 Valid Issuance. The Shares have been duly and validly authorized and, when issued and paid for pursuant to
this Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities
laws or encumbrances or restrictions established by or through the Investor. The Warrant has been duly and validly authorized. Upon the due exercise of the Warrant, the Warrant Shares will be validly issued, fully paid and non-assessable
free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. The Company has reserved a sufficient number of shares of Common Stock for
issuance upon the exercise of the Warrant, free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. 

4.5 Consents. The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and
sale of the Securities require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official, other than post-sale filings pursuant to applicable state and federal securities laws which the Company
undertakes to file within the applicable time periods. As of the date of this Agreement, the Company has taken all action necessary to exempt (a) the issuance and sale of the Securities, (b) the issuance of the Warrant Shares upon due
exercise of the Warrant, and (c) the other transactions contemplated by the Transaction Documents from the provisions of any anti-takeover, business combination or control share law or statute binding on the Company or to

  
 -4-

 
which the Company may be subject or any provision of the Certificate of Incorporation, Bylaws or any stockholder rights agreement that is or could become applicable to the Investor as a result of
the transactions contemplated hereby, including without limitation, the issuance of the Securities and the ownership, disposition or voting of the Securities by the Investor or the exercise of any right granted to the Investor pursuant to this
Agreement or the other Transaction Documents. 
 4.6 SEC Filings. The Company has filed all reports required to be
filed by it under the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a) or 15(d) of the Exchange Act, for the 12 months preceding the date hereof
(collectively, the “SEC Filings”) on a timely basis or has timely filed a valid extension of such time of filing and has filed any such SEC Filings prior to the expiration of any such extension. As of their respective dates,
the SEC Filings complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the Securities and Exchange Commission promulgated thereunder, and none of the SEC Filings, when
filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not
misleading. The Company does not have pending before the Securities and Exchange Commission any unresolved or outstanding comments from the Securities and Exchange Commission with respect to any SEC Filings or any request for confidential treatment
of information. 
 4.7 No Material Adverse Change. Since December 31, 2010, except as identified and described
in the SEC Filings, there has not been: 
 (a) any change in the consolidated assets, liabilities, financial condition or
operating results of the Company from that reflected in the financial statements included in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2010, except for changes in the ordinary course of
business which have not and could not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 
 (b) any declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the Company, or any redemption or repurchase of any securities of the
Company; 
 (c) any damage, destruction or loss, whether or not covered by insurance to any assets or properties of the Company
or the Subsidiary which has had or is reasonably likely to have a Material Adverse Effect, individually or in the aggregate; 

(d) any waiver by the Company or the Subsidiary of a right or of a debt owed to it which waiver has had or is reasonably likely to have
a Material Adverse Effect, individually or in the aggregate; 

  
 -5-

 (e) any satisfaction or discharge of any lien, claim or encumbrance or payment of any
obligation by the Company or the Subsidiary, except which has not and will not have a Material Adverse Effect, individually or in the aggregate; 
 (f) any change or amendment to the Certificate of Incorporation or Bylaws, or material change to or termination of any Material Contract; 

(g) any material labor difficulties or labor union organizing activities with respect to employees of the Company or the Subsidiary;

 (h) any material transaction entered into by the Company or the Subsidiary other than in the ordinary course of business;

 (i) the loss of the services of any key employee, or material change in the composition or duties of the senior management
of the Company or the Subsidiary; 
 (j) any change in the Company’s method of accounting or the identity of its auditors;

 (k) any issuances of any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock
option plans; 
 (l) the loss or threatened loss of any customer which has had or could reasonably be expected to have a
Material Adverse Effect; or 
 (m) any other event, occurrence, development or condition of any character that has had or could
reasonably be expected to have a Material Adverse Effect. 
 4.8 No Conflict, Breach, Violation or Default. The
execution, delivery and performance of the Transaction Documents by the Company and the issuance and sale of the Securities will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default
under (a) the Certificate of Incorporation or the Bylaws, both as in effect on the date hereof, (b) any statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the
Company, any Subsidiary or any of their respective assets or properties, or (c) any Material Contract. 
 4.9 Financial
Statements. The financial statements included in each SEC Filing present fairly, in all material respects, the consolidated financial position of the Company as of the dates shown and its consolidated results of operations and cash flows
for the periods shown, subject, in the case of unaudited statements, to normal, year-end audit adjustments, and such financial statements have been prepared in conformity, and comply in all material respects, with United States generally accepted
accounting principles applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto. Except as set forth in the financial statements of the Company included in
the SEC Filings filed prior to the date hereof, neither the Company nor the Subsidiary has incurred any liabilities, contingent or otherwise, except liabilities which have not had nor could reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. 

  
 -6-

 4.10 Compliance with Nasdaq Continued Listing Requirements. As of the date
hereof, the Company is in compliance with applicable Nasdaq continued listing requirements and there are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the
Company’s Common Stock on Nasdaq. In the two years preceding the date hereof, the Company has not received any notice of, nor to the Company’s Knowledge is there any basis for, the delisting of the Common Stock from Nasdaq. 

4.11 Brokers and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid
right, interest or claim against or upon the Company, the Subsidiary or the Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company. 

4.12 No Directed Selling Efforts or General Solicitation. Neither the Company nor any Person acting on its behalf has
conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any of the Securities. 
 4.13 No Integrated Offering. Neither the Company nor any of its Affiliates or any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any Company
security or solicited any offers to buy any security, under circumstances that would adversely affect reliance by the Company on the exemption from registration under Section 4(2) of the Securities Act of 1933, as amended (the
“Securities Act”) or would require registration of the Securities under the Securities Act. 
 4.14 Private
Placement. Assuming the accuracy of the Investor’s representations and warranties set forth in Sections 5.3, 5.4, 5.8 and 5.9 of this Agreement, the offer and sale of the Securities to the Investor as
contemplated hereby is exempt from the registration requirements of the Securities Act. 
 4.15 Material Contracts. All
Material Contracts are valid and in full force and effect and enforceable in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability
relating to or affecting creditors’ rights and general equity principles, except to the extent that the failure to be in full force and effect would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor the
Subsidiary, nor, to the Company’s Knowledge, any counterparty to any such Material Contract, has violated any provision of, or committed or failed to perform any act which, with or without notice, lapse of time or both, would constitute a
default under, or give rise to a right of termination, modification or cancellation under the provisions of any Material Contract. Neither the Company nor the Subsidiary has received written notice that it has breached, violated or defaulted under
any Material Contract. 

  
 -7-

 4.16 Litigation. There is no action, suit, inquiry, notice of violation, proceeding
(including any partial proceeding such as a deposition) or investigation pending or threatened in writing against or affecting the Company, the Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or
administrative agency, regulatory authority (federal, state, county, local or foreign), stock market, stock exchange or trading facility (together an “Action”) which (i) adversely affects or challenges the legality, validity or
enforceability of any of the Transaction Documents or the Securities or (ii) except as specifically disclosed in the SEC Filings, could, if there were an unfavorable decision, individually or in the aggregate, have or reasonably be expected to
result in a Material Adverse Effect. Neither the Company nor the Subsidiary, nor any director or officer thereof (in his or her capacity as such), is or has been the subject of any Action involving a claim of violation of or liability under federal
or state securities laws or involving a claim of breach of fiduciary duty, except as specifically disclosed in the SEC Filings. There has not been, and to the Company’s Knowledge, there is not pending any investigation by the Securities and
Exchange Commission involving the Company or any current or former director or officer of the Company (in his or her capacity as such). The Securities and Exchange Commission has not issued any stop order or other order suspending the effectiveness
of any registration statement filed by the Company or the Subsidiary under the Exchange Act or the Securities Act. 
 4.17
Intellectual Property. 
 (a) The business of the Company and the Subsidiary as currently conducted does not require or
use any Intellectual Property not owned by or licensed to the Company or the Subsidiary. Neither the Company nor the Subsidiary is obligated to make any payment or grant any rights to any third party in respect of any Intellectual Property used by
the Company or the Subsidiary or in connection with the business of the Company and the Subsidiary as currently conducted. 

(b) To the Company’s Knowledge, there has not been, and there is not now, any material unauthorized use, infringement or
misappropriation by any third party, including without limitation any employee, of any of the Intellectual Property owned or licensed by the Company. No shareholder or employee of, or consultant to, the Company has any right to use, other than in
connection with the business activities of the Company as presently conducted, any of the Company’s Intellectual Property. 
 (c) The Company has taken (and caused its Subsidiary to take) reasonable precautions to protect the secrecy, confidentiality and value of its trade secrets. The Company has obtained (and caused its
Subsidiary to obtain) valid and effective work made for hire agreements and assignments from all current and former Employees, independent contractors and former independent contractors (collectively, the “Inventors”) of all such
Inventors’ rights in any of the Company’s Intellectual Property developed by such Inventors. 
 4.18 Internal
Accounting Controls. The Company and the Subsidiary maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in 

  
 -8-

 
conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or
specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including the Subsidiary, is made
known to the certifying officers by others within those entities, particularly during the period in which the Company’s Form 10-K or 10-Q, as the case may be, is being prepared. The Company’s certifying officers have evaluated the
effectiveness of the Company’s controls and procedures in accordance with Item 307 of Regulation S-K under the Exchange Act for the Company’s most recently ended fiscal quarter or fiscal year-end (such date, the
“Evaluation Date”). The Company presented in its most recently filed Form 10-K or Form 10-Q the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their
evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term is defined in Item 308(c) of Regulation S-K under the Exchange Act) or, to the
Company’s Knowledge, in other factors that could significantly affect the Company’s internal controls. 
 4.19 Tax
Matters. As of December 31, 2010, the Company had a net operating loss carry forward (as determined for federal income tax purposes), of approximately $788 million. As of the date hereof (taking into account the transactions contemplated by
the Transaction Documents), no material portion of the Company’s net operating loss carry forward is subject to a limitation under the Internal Revenue Code of 1986, as amended, and/or the income tax regulations promulgated there under,
including Section 382, Section 383 or under consolidated income tax rules. Neither the Company nor any other member of its affiliated group has any material liability for taxes of any person (other than the Company and its affiliated group
members) (A) under Treas. Reg. § 1.1502-6 (or any similar provision of state, local or non-U.S. law), (B) as a transferee or successor, (C) by contract, or (D) otherwise. 

5. Representations and Warranties of the Investor. The Investor hereby represents and warrants to the Company that:

 5.1 Organization and Existence; Ownership of Common Stock. The Investor is a validly existing limited liability
company and has all requisite limited liability company power and authority to invest in the Securities pursuant to this Agreement. Immediately prior to the purchase by the Investor of the Shares contemplated by this Agreement, the Investor
beneficially owned 1,089,810 shares of Common Stock. As of the date hereof, other than the shares referenced in the immediately preceding sentence, neither the Investor nor its Affiliates has any direct or indirect ownership interest in any shares
of Common Stock or any derivative rights such as puts or calls relating to the Common Stock. 
 5.2
Authorization. The execution, delivery and performance by the Investor of the Transaction Documents to which the Investor is a party have been duly authorized and will each constitute the valid and legally binding obligation of the
Investor, enforceable against the Investor in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting
creditors’ rights generally. 

  
 -9-

 5.3 Purchase Entirely for Own Account. The Securities to be received by the
Investor hereunder will be acquired for the Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention of
selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act. Subject to the immediately preceding sentence, nothing contained herein shall be deemed a representation or warranty by the Investor
to hold the Securities for any period of time. The Investor is not a registered broker dealer or an entity engaged in the business of being a broker dealer. 
 5.4 Investment Experience. The Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial
or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby. The Investor also represents it has not been organized for the purpose of acquiring the Shares. 

5.5 Disclosure of Information. The Investor has had an opportunity to receive all additional information related to the
Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities. The Investor acknowledges that it has reviewed the SEC
Filings.
 5.6 Restricted Securities. The Investor understands that the Securities are characterized as
“restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be
resold without registration under the Securities Act only in certain limited circumstances. 
 5.7 Legends. It is
understood that, except as provided below, certificates evidencing such Securities may bear the following or any similar legend: 
 (a) “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS, AND MAY NOT BE
OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, OR (II) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
SATISFACTORY TO IT THAT SUCH REGISTRATION IS NOT REQUIRED OR THAT SUCH SECURITIES TO BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED ARE BEING OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION
REQUIREMENTS.” 

  
 -10-

 (b) If required by the authorities of any state in connection with the issuance of sale of
the Securities, the legend required by such state authority.
 5.8 Accredited Investor. The Investor is an
accredited investor as defined in Rule 501(a) of Regulation D, as amended, under the Securities Act. 
 5.9 No General
Solicitation. The Investor did not learn of the investment in the Securities as a result of any public advertising or general solicitation. 
 5.10 Brokers and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company, the Subsidiary or
the Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Investor. 
 6. Covenants and Other Agreements. 
 6.1 Reservation of Common
Stock. The Company shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of providing for the exercise of the Warrant, such number of shares of Common Stock as shall
from time to time equal the number of shares sufficient to permit the exercise of the Warrant issued pursuant to this Agreement in accordance with their respective terms. 
 6.2 Continued Listing of Shares and Related Matters. So long as the Investor owns the Securities, the Company will use commercially reasonable efforts to continue the listing and trading of
its Common Stock on the Nasdaq and, in accordance therewith, will use commercially reasonable efforts to comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of such market or exchange, as
applicable. 
 6.3 Publicity. No public announcement or disclosure concerning the transactions contemplated hereby
shall be issued by the Company or the Investor without the prior consent of the Company (in the case of a release or announcement by the Investor) or the Investor (in the case of a release or announcement by the Company), which consents shall not be
unreasonably withheld, except as such announcement or disclosure may be required by law or the applicable rules or regulations of any securities exchange or securities market. 
 6.4 Further Assurances. The parties hereto shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the
transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. 
 7. Survival and
Indemnification. 
 7.1 Survival. All representations, warranties, covenants and agreements contained in this
Agreement shall be deemed to be representations, warranties, covenants and agreements as of the date hereof and shall survive the execution and delivery of this Agreement for a period of one (1) year from the date of this Agreement;
provided, however, that the 

  
 -11-

 
provisions contained in Section 6 hereof shall survive in accordance therewith; provided, further, that the representations and warranties of the Company set forth in this
Agreement in Section 4.19 (Tax Matters) shall survive the execution and delivery of this Agreement for a period of five (5) years from the date of this Agreement. 

7.2 Indemnification. The Company agrees to indemnify and hold harmless, on an after insurance recovery basis, the Investor
and its directors, officers, employees and agents from and against any and all losses, claims, damages, liabilities and expenses (including, without limitation, reasonable attorney fees and disbursements and other expenses incurred in connection
with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement hereof) (collectively, “Losses”) to which such Person may become subject as a result of any breach of
representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person; provided,
however, the aggregate liability of the Company for indemnification claims under this Section 7.2 shall not exceed an amount equal to the Purchase Price. 
 7.3 Conduct of Indemnification Proceedings. Promptly after receipt by any Person (the “Indemnified Person”) of notice of any demand, claim or circumstances which would or
might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which Indemnity may be sought pursuant to Section 7.2, such Indemnified Person shall promptly notify the Company in writing and the
Company shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses; provided however, that the
failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder except to the extent that the Company is materially prejudiced by such failure to notify. In any such proceeding, any
Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the
retention of such counsel; or (ii) in the reasonable judgment of counsel to such Indemnified Person representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. The
Company shall not be liable for any settlement of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, conditioned or delayed, but if settled with such consent, or if there be a final judgment for
the plaintiff, the Company shall indemnify and hold harmless such Indemnified Person from and against any loss or liability (to the extent stated above) by reason of such settlement or judgment. Without the prior written consent of the
Indemnified Person, which consent shall not be unreasonably withheld, conditioned or delayed, the Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a
party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Person from all liability arising out of such proceeding. 

  
 -12-

 8. Miscellaneous. 

8.1 Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the
Company or the Investor, as applicable. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 8.2 Counterparts; Execution. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile or portable document format (PDF), which shall be deemed an original. 

8.3 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 
 8.4 Notices. Unless otherwise provided, any notice
required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given
by facsimile, then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or
(B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one day after delivery to such
carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the other party: 

If to the Company: 
 InfoSpace, Inc. 
 601 108th Avenue NE, Suite 1200 

Bellevue, WA 98004 
 Attention: General Counsel 
 Fax: 425.201.6167 

With a copy to: 
 Perkins Coie LLP 
 1201 Third Avenue, Suite 4800 

Seattle, WA 98101 
 Attention: Andrew Bor 
 Fax: 206.359.9577 

  
 -13-

 If to the Investor: 

Cambridge Information Group I LLC 
 c/o Cambridge Information Group, Inc. 
 7200 Wisconsin Avenue, Suite 601

 Bethesda, Maryland 20814 USA 
 Attention: Larisa A. Trainor, Esq. 
 Fax: 301.961.6790 

With a copy to: 
 Fried, Frank, Harris, Shriver & Jacobson LLP 
 801
17th Street, NW 

Washington, D.C. 20006 
 Attention: Brian Mangino 
 Fax: 202.639.70003 

8.5 Expenses. The parties hereto shall pay their own costs and expenses in connection herewith; provided,
however, notwithstanding the foregoing, the Company agrees to reimburse the Investor for fifty percent (50%) of the Investor’s legal fees incurred in connection with the Transaction Documents and the transactions contemplated herein
and therein, up to a maximum reimbursement amount of $20,000. 
 8.6 Amendments and Waivers. Any term of this
Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investor. Any
amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Securities purchased under this Agreement at the time outstanding, each future holder of all such securities, and the Company. 

8.7 Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by
applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any
provision of law which renders any provision hereof prohibited or unenforceable in any respect. 
 8.8 Entire
Agreement. This Agreement, including the Exhibits and the Disclosure Schedules, and the other Transaction Documents constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof. 

  
 -14-

 8.9 Governing Law; Consent to Jurisdiction. This Agreement shall be governed by,
and construed in accordance with, the internal laws of the State of Delaware without regard to the choice of law principles thereof. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of
Washington located in King County and the United States District Court for the Western District of Washington for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated
hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the
parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such
suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 

[signature page follows] 

  
 -15-

 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly
authorized officers to execute this Agreement as of the date first above written. 
  

							
	The Company:	 	INFOSPACE, INC.
			
		 	By:	 	/s/ William Ruckelshaus
		 		 		 	  

		 	Name:	 	William Ruckelshaus
		 	Title:	 	CEO and President

							
		
	The Investor:	 	CAMBRIDGE INFORMATION GROUP I LLC
			
		 	By:	 	/s/ Andrew Snyder
		 		 		 	  

		 	Name:	 	Andrew Snyder
		 	Title:	 	CEO

 Exhibit B to Securities Purchase AgreementWarrant to Purchase Common Stock

 Exhibit 10.2 
 THE SECURITIES REPRESENTED HEREBY AND ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES
LAWS, AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, OR (II) THE COMPANY HAS RECEIVED AN OPINION OF
COUNSEL SATISFACTORY TO IT THAT SUCH REGISTRATION IS NOT REQUIRED OR THAT SUCH SECURITIES TO BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED ARE BEING OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION
REQUIREMENTS. 
 SUBJECT TO THE PROVISIONS OF SECTION 10 HEREOF, THIS WARRANT SHALL BE VOID AFTER 5:00 P.M. EASTERN TIME ON AUGUST 23,
2014, AS SUCH DATE MAY BE EXTENDED IN ACCORDANCE WITH SECTION 10 HEREOF (THE “EXPIRATION DATE”). 
  

			
	Warrant No.: 2011-W-1	  	Number of Shares: 1,000,000

INFOSPACE, INC. 
 WARRANT TO PURCHASE 
 COMMON STOCK 

For value received, Cambridge Information Group I LLC, a Delaware limited liability company (“Warrantholder”), is
entitled to purchase, subject to the provisions of this Warrant, from InfoSpace, Inc., a Delaware corporation (the “Company”), at any time beginning on August 23, 2011 and not later than 5:00 P.M., Eastern time, on the
Expiration Date (as defined above), at an exercise price per share equal to $9.62 (the exercise price in effect being herein called the “Warrant Price”), 1,000,000 shares (“Warrant Shares”) of the Company’s
Common Stock, par value $0.0001 per share (“Common Stock”). The number of Warrant Shares purchasable upon exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time as described herein. This
Warrant has been issued pursuant to the terms of that certain Securities Purchase Agreement dated August 23, 2011 between the Company and Warrantholder (the “Purchase Agreement”). Capitalized terms used but not defined herein
shall have the respective meanings set forth in the Purchase Agreement. 
 Section 1. Registration. The Company
shall maintain books for the transfer and registration of the Warrant. Upon the initial issuance of this Warrant, the Company shall issue and register the Warrant in the name of the Warrantholder. 

Section 2. Transfers. Except for a transfer or assignment to an Affiliate of the Warrantholder or an employee of
Cambridge Information Group, Inc., a Maryland corporation (“CIG”) (in the case of a transfer or assignment to an employee of CIG, not to exceed 10% of the Warrant Shares, in the aggregate), this Warrant may not be transferred or
assigned by the 

 
Warrantholder to any Person without the prior written consent of the Company (which may be withheld for any reason). Subject to such restrictions, the Company shall transfer this Warrant from
time to time upon the books to be maintained by the Company for that purpose, upon surrender thereof for transfer properly endorsed or accompanied by appropriate instructions for transfer and such other documents as may be reasonably required by the
Company, including, if required by the Company, an opinion of its counsel to the effect that such transfer is exempt from the registration requirements of the Securities Act and applicable state securities laws and a new Warrant shall be issued to
the transferee and the surrendered Warrant shall be canceled by the Company. 
 Section 3. Exercise of Warrant.

 (a) Subject to Section 17 and the other provisions hereof, the Warrantholder may exercise this Warrant in whole
or in part at any time after August 23, 2011 and prior to the Expiration Date upon surrender of the Warrant, together with delivery of the duly executed Warrant exercise form attached hereto as Appendix A (the “Exercise
Agreement”) and payment by cash, certified check or wire transfer of funds for the aggregate Warrant Price for that number of Warrant Shares then being purchased, to the Company during normal business hours on any business day at the
Company’s principal executive offices (or such other office or agency of the Company as it may designate by notice to the holder hereof). The Warrant Shares so purchased shall be deemed to be issued to the holder hereof, as the record
owner of such shares, as of the close of business on the date on which this Warrant shall have been surrendered (or evidence of loss, theft or destruction thereof and security or indemnity satisfactory to the Company), the Warrant Price shall have
been paid and the completed Exercise Agreement shall have been delivered. Certificates for the Warrant Shares so purchased, representing the aggregate number of shares specified in the Exercise Agreement, shall be delivered to the holder hereof
within a reasonable time, not exceeding five (5) business days, after the date this Warrant shall have been so exercised. If this Warrant shall have been exercised only in part, then, unless this Warrant has expired, the Company shall, at
its expense, at the time of delivery of such certificates, deliver to the holder a new Warrant representing the number of shares with respect to which this Warrant shall not then have been exercised. As used herein, “business
day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business. Each exercise hereof shall constitute an affirmation by the Warrantholder that the representations and
warranties contained in Section 5 of the Purchase Agreement are true and correct in all material respects with respect to the Warrantholder as of the time of such exercise. 

Section 4. Compliance with the Securities Act of 1933. The Company may cause the legend set forth on the first page of this
Warrant to be set forth on each Warrant or cause a similar legend to be set forth on any certificates evidencing Warrant Shares or other securities issued upon exercise of this Warrant, unless counsel for the Company is of the opinion as to any such
security that such legend is unnecessary. 
 Section 5. Payment of Taxes. The Company will pay any documentary
stamp taxes attributable to the initial issuance of Warrant Shares issuable upon the exercise of the Warrant; provided, however, that the Company shall not be required to pay any tax or taxes which may be payable in respect of any transfer involved
in the issuance or delivery of any certificates for 

  
 -2-

 
Warrant Shares in a name other than that of the registered holder of this Warrant in respect of which such shares are issued, and in such case, the Company shall not be required to issue or
deliver any certificate for Warrant Shares or any Warrant until the person requesting the same has paid to the Company the amount of such tax or has established to the Company’s reasonable satisfaction that such tax has been paid. The
holder shall be responsible for income taxes due under federal, state or other law, if any such tax is due. 
 Section 6.
Mutilated or Missing Warrants. In case this Warrant shall be mutilated, lost, stolen, or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation of the mutilated Warrant, or in lieu
of and substitution therefor, a new Warrant of like tenor and for the purchase of a like number of Warrant Shares, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction of the Warrant, and with
respect to a lost, stolen or destroyed Warrant, reasonable indemnity or bond with respect thereto, if requested by the Company. The holder of such mutilated, lost, stolen or destroyed Warrant shall also pay any reasonable third-party costs
associated with the issuance of the replacement Warrant. If a replacement Warrant is requested due to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a
replacement. 
 Section 7. Reservation of Common Stock. The Company hereby represents and warrants that there
have been reserved, and the Company shall at all applicable times keep reserved until issued (if necessary) as contemplated by this Section 7, out of the authorized and unissued shares of Common Stock, sufficient shares to provide for
the exercise of the rights of purchase represented by this Warrant. The Company agrees that all Warrant Shares issued upon due exercise of the Warrant shall be, at the time of delivery of the certificates for such Warrant Shares, duly
authorized, validly issued, fully paid and non-assessable shares of Common Stock of the Company. 
 Section 8.
Adjustments. Subject and pursuant to the provisions of this Section 8, the Warrant Price and number of Warrant Shares subject to this Warrant shall be subject to adjustment from time to time as set forth hereinafter.

 (a) If the Company shall, at any time or from time to time while this Warrant is outstanding, (i) pay a dividend or make
a distribution on its Common Stock in shares of Common Stock, or (ii) subdivide (by any stock split, reclassification or otherwise) its outstanding shares of Common Stock into a greater number of shares, then the Warrant Price in effect
immediately prior to the date upon which such change shall become effective shall be proportionately reduced and the number of Warrant Shares purchasable upon exercise of the Warrant shall be proportionately increased. If the Company at any time
combines (by reverse stock split, reclassification or otherwise) its outstanding shares of Common Stock into a smaller number of shares, then the Warrant Price in effect immediately prior to the date upon which such change shall become effective
shall be proportionately increased and the number of Warrant Shares purchasable upon exercise of the Warrant shall be proportionately decreased. Such adjustments shall be effective at the close of business on the date the dividend, subdivision or
combination becomes effective. 

  
 -3-

 (b) If any capital reorganization of the Company, reclassification of the capital stock of
the Company (other than a change in par value or from par value to no par value or from no par value to par value or as a result of a stock dividend or subdivision, split-up or combination of shares), consolidation or merger of the Company with or
into another corporation in which the Company is not the survivor, or sale, transfer or other disposition of all or substantially all of the Company’s assets to another corporation shall be effected (in each case which entitles the holders of
Common Stock to receive stock, securities or assets with respect to or in exchange for Common Stock), then, as a condition of such reorganization, reclassification, consolidation, merger, sale, transfer or other disposition, lawful and adequate
provision shall be made whereby each Warrantholder shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions herein specified and in lieu of the Warrant Shares immediately theretofore issuable upon
exercise of the Warrant, such shares of stock, securities or assets as would have been issuable or payable with respect to or in exchange for a number of Warrant Shares equal to the number of Warrant Shares immediately theretofore issuable upon
exercise of the Warrant, had such reorganization, reclassification, consolidation, merger, sale, transfer or other disposition not taken place, and in any such case appropriate provision shall be made with respect to the rights and interests of each
Warrantholder to the end that the provisions hereof (including, without limitation, provision for adjustment of the Warrant Price) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any shares of stock,
securities or assets thereafter deliverable upon the exercise thereof. The provisions of this paragraph (b) shall not apply to a Change of Control (as defined in Section 10(c)) occurring after August 23, 2014. 

(c) If at any time after the date hereof, but prior to the date that is twenty-four (24) months from the date hereof, the Company
shall fix a record date for the making of a distribution to holders of Common Stock of evidences of indebtedness, assets or any other property (including cash or subscription rights, but excluding securities for which an adjustment is provided
pursuant to Section 8(a)) (the “Property”), in each such case, the Warrant Price to be in effect after such record date shall be equal to the Warrant Price in effect immediately before such record date less the fair
market value of the evidences of indebtedness, assets or other property to be distributed per share of Common Stock in such distribution (in the case of a cash dividend, the amount of cash to be distributed per share of Common Stock in such
distribution). Such adjustments shall be made successively whenever such a record date is fixed; and in the event that such distribution is not so made, the Warrant Price shall again be adjusted to be the Warrant Price which would then be in effect
if such record date had not been fixed. The fair market value of the Property shall be determined by the Board of Directors of the Company (the “Board”) in good faith; provided, that the Company shall promptly notify
the Warrantholder of such determination and, in the event the Warrantholder disagrees with such determination, then it shall provide written notice to the Company to that effect given not later than thirty (30) days following the Company’s
notice of the Board’s determination of fair market value, and the Warrantholder and the Company shall attempt to resolve such dispute by negotiation in good faith. 
 (d) For the term of this Warrant, in addition to the provisions contained above, the Warrant Price shall be subject to adjustment as provided below. An adjustment to the Warrant Price shall become
effective immediately after the payment date in the case of each dividend or distribution and immediately after the effective date of each other event which requires an adjustment. 

  
 -4-

 (e) In the event that, as a result of an adjustment made pursuant to this
Section 8, the holder of this Warrant shall become entitled to receive any shares of capital stock of the Company other than shares of Common Stock, the number of such other shares so receivable upon exercise of this Warrant shall be
subject thereafter to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Warrant Shares contained in this Warrant. 

(f) Except as otherwise provided in Section 8(h) hereof, if prior to the Expiration Date, the Company issues or sells, or in
accordance with Section 8(g) is deemed to have issued or sold, any shares of Common Stock for no consideration (other than a stock split or stock dividend) or for a consideration per share less than $9.16 (the “Common Stock
Purchase Price”) (a “Dilutive Issuance”), then effective immediately upon such Dilutive Issuance, the Warrant Price will be adjusted in accordance with the following formula: 

 

							
	
                      
              AWP
	  	=	  	 (WP)(CSOP + P/WP)
	  	
		  		  	        (CSOA)	  	

  

									
				
		  	AWP	  	 	=	  	  	the adjusted Warrant Price;
	where:	  	WP	  	 	=	  	  	the then current Warrant Price;
		  	CSOP	  	 	=	  	  	the number of shares of Common Stock deemed outstanding immediately prior to the Dilutive Issuance, which shall include the actual number of shares outstanding, plus all shares
issuable upon the conversion or exercise of all outstanding convertible securities, warrants and options, in each case prior to giving effect to the Dilutive Issuance;
		  	P	  	 	=	  	  	the aggregate consideration, calculated as set forth in Section 8(g)(v), received by the Company upon such Dilutive Issuance; and
		  	CSOA	  	 	=	  	  	the total number of shares of Common Stock deemed outstanding immediately after the Dilutive Issuance which shall include the actual number of shares outstanding plus all shares
issuable upon the conversion or exercise of all outstanding convertible securities, warrants and options, in each case after giving effect to the Dilutive Issuance.

 (g) Effect on Warrant Price of Certain Events. For purposes of determining the adjusted
Warrant Price under Section 8(f), the following will apply: 
 (i) Issuance of Rights, Options or Convertible
Securities. Subject to Section 8(g)(ii) below, if the Company issues or grants any warrants, rights or options, whether or not immediately exercisable, to subscribe for or to purchase Common Stock or Convertible Securities (as
defined below) (such warrants, rights and options to purchase Common Stock or Convertible Securities are hereinafter referred to as “Options”), and the price per share for which Common Stock is purchasable or issuable upon the
exercise of such Options (as determined 

  
 -5-

 
below) is less than the Common Stock Purchase Price on the date of issuance of such Option (collectively, “Below Market Options”), then the maximum total number of shares of
Common Stock issuable upon the exercise of all such Below Market Options (assuming full exercise, conversion or exchange of Convertible Securities, if applicable) will, as of the date of the issuance or grant of such Below Market Options, be deemed
to be outstanding and to have been issued and sold by the Company for such price per share. For purposes of the preceding sentence, the price per share for which Common Stock is issuable upon the exercise of such Below Market Options is
determined by dividing (i) the total amount, if any, received or receivable by the Company as consideration for the issuance or sale of all such Below Market Options, plus the minimum aggregate amount of additional consideration, if any,
payable to the Company upon the exercise of all such Below Market Options, plus, in the case of Convertible Securities issuable upon the exercise of such Below Market Options, the minimum aggregate amount of additional consideration payable upon the
conversion or exchange thereof at the time such Convertible Securities first become convertible or exchangeable, by (ii) the maximum total number of shares of Common Stock issuable upon the exercise of all such Below Market Options (assuming
full conversion or exchange of Convertible Securities, if applicable). No further adjustment to the Warrant Price will be made upon the exercise of such Below Market Options or upon the conversion or exchange of Convertible Securities issuable upon
exercise of such Below Market Options. 
 (ii) Issuance of Convertible Securities. If the Company issues or sells (other
than upon the exercise of Below Market Options with respect to which the Warrant Price was previously adjusted) any debt or equity security directly or indirectly convertible into or exchangeable for Common Stock (“Convertible
Securities”), whether or not immediately convertible or exchangeable, and the price per share for which Common Stock is issuable upon such conversion or exchange (as determined below) is less than the Common Stock Purchase Price on the date
of issuance of such Convertible Security, then the maximum total number of shares of Common Stock issuable upon the conversion or exchange of all such Convertible Securities will, as of the date of the issuance of such Convertible Securities, be
deemed to be outstanding and to have been issued and sold by the Company for such price per share. For the purposes of the preceding sentence, the price per share for which Common Stock is issuable upon such conversion or exchange is determined
by dividing (A) the total amount, if any, received or receivable by the Company as consideration for the issuance or sale of all such Convertible Securities, plus the minimum aggregate amount of additional consideration, if any, payable to the
Company upon the conversion or exchange thereof at the time such Convertible Securities first become convertible or exchangeable, by (B) the maximum total number of shares of Common Stock issuable upon the conversion or exchange of all such
Convertible Securities. No further adjustment to the Warrant Price will be made upon the actual issuances of such Common Stock upon conversion or exchange of such Convertible Securities. 

(iii) Change in Option Price or Conversion Rate. If there is a change at any time in (i) the amount of additional
consideration payable to the Company upon the exercise of any Options; (ii) the amount of additional consideration, if any, payable to the Company upon the conversion or exchange of any Convertible Securities, or (iii) the rate at which
any Convertible Securities are convertible into or exchangeable for Common Stock (other than under or by reason of provisions designed to protect against dilution), the Warrant Price in effect at

  
 -6-

 
such time shall be adjusted to the Warrant Price which would have been in effect had such Options or Convertible Securities still outstanding provided for such changed additional consideration or
changed conversion rate, as the case may be, at the time initially granted, issued or sold. 
 (iv) Treatment of Expired
Options and Unexercised Convertible Securities. If, in any case, the total number of shares of Common Stock issuable upon exercise of any Options or upon conversion or exchange of any Convertible Securities is not, in fact, issued and the
rights to exercise such Option or to convert or exchange such Convertible Securities shall have expired or terminated, the Warrant Price then in effect will be readjusted to the Warrant Price which would have been in effect at the time of such
expiration or termination had such Options or Convertible Securities, to the extent outstanding immediately prior to such expiration or termination (other than in respect of the actual number of shares of Common Stock issued upon exercise,
conversion or exchange thereof), never been issued. 
 (v) Calculation of Consideration Received. If any Common
Stock, Options or Convertible Securities are issued, granted or sold for cash, the consideration received therefor for purposes of this Warrant will be the amount received by the Company therefor, before deduction of reasonable commissions,
underwriting discounts or allowances or other reasonable expenses paid or incurred by the Company in connection with such issuance, grant or sale. In case any Common Stock, Options or Convertible Securities are issued or sold for a
consideration part or all of which shall be other than cash, the amount of the consideration other than cash received by the Company will be the fair market value of such consideration as determined in the good faith reasonable business judgment of
the Board of Directors. 
 (h) Exceptions to Adjustment of Warrant Price. No adjustment to the Warrant Price or the
number of Warrant Shares issuable pursuant to this Warrant will be made under Section 8(f) above as a result of (i) the grant or exercise of any stock or options which may hereafter be granted or exercised under any employee,
consultant or director incentive or benefit plan of the Company now existing or implemented in the future, so long as the issuance of such stock or options is approved by the Company’s Board of Directors or the Compensation Committee of the
Company’s Board of Directors; (ii) the sale, issuance or grant of any options, warrant, convertible securities or rights or agreements to purchase securities of the Company outstanding on the date hereof; (iii) any securities issued
for consideration other than cash pursuant to a merger, consolidation, acquisition or similar business combination approved by the Company’s Board of Directors; (iv) shares of Common Stock issued in connection with any stock split, stock
dividend or reclassification or similar transaction (for which an adjustment is made pursuant to Section 8(a) or 8(b) hereof); (v) shares of Common Stock issued upon exercise of the Warrant; (vi) any securities issued
pursuant to any equipment leasing or debt financing arrangement from a bank or similar financial institution whose primary business is lending money and not investing in securities, provided that such arrangement is approved by the Company’s
Board of Directors; (vii) any securities issued in connection with strategic transactions involving the Company and other entities, including (A) joint ventures, manufacturing, marketing or distribution arrangements, (B) technology
transfer or development arrangements, provided that such arrangement is approved by the Company’s Board of Directors; or (viii) an agreement to issue securities which does not close. 

  
 -7-

 Section 9. Fractional Interest. The Company shall not be required to issue
fractions of Warrant Shares upon the exercise of this Warrant, and the number of Warrant Shares issued upon exercise of this Warrant shall be rounded down to the nearest whole number.

Section 10. Extension of Expiration Date.
 (a) If, prior to August 23, 2014, the Company has consummated an acquisition, distribution, transfer or other purchase of assets or equity interests, merger, consolidation, joint venture,
partnership, business combination, tender or exchange offer, recapitalization, or similar transaction, in one or more transactions; provided that such company or business is not owned in whole or in part by Warrantholder (each, a
“Target,” and such transaction with a Target, a “Transaction”) with a Transaction Value equal to or greater than $200 million in the aggregate (an “Extension Expiration Event”), then the Expiration
Date of this Warrant shall be extended to the earlier of (i) August 23, 2017 and (ii) the effective date of a Change of Control (as defined below) of the Company. 

(b) For purposes of this Warrant, “Transaction Value” shall mean the sum of (i)(A) in the case of a Transaction
involving the capital stock of a Target, the total fair market value (at the time of closing) of all consideration paid or payable, or otherwise to be distributed, directly or indirectly, in respect of a share of Target capital stock in connection
with the Transaction multiplied by the Target’s Fully Diluted Shares Outstanding (as defined below) and (B) in the case of a Transaction involving assets of the Target, the total fair market value (at the time of closing) of all
consideration paid or payable, directly or indirectly, to the Target in connection with the Transaction, plus (without duplication) (ii) the amount of all indebtedness for borrowed money, preferred stock, capital leases and any other
liabilities and obligations for borrowed money on the Target business’ financial statements immediately following the closing or directly or indirectly assumed, retired, repaid, redeemed or defeased in connection with a Transaction, plus
(iii) the aggregate fair market value (at the time of any closing) of any other consideration (tangible or intangible) paid by the Company and less (iv) any cash, cash equivalents, or marketable securities directly or indirectly
assumed in connection with the Transaction. Any amounts to be paid contingent upon future events shall be estimated for the purposes of calculating the Transaction Value at their expected net present value at the time of execution of a definition
agreement with respect to such Transaction; any amounts held in escrow shall be deemed paid at closing. “Fully Diluted Shares Outstanding” means the total number of shares of common stock outstanding plus the total net number of
shares calculated on a “treasury stock” basis of common stock issuable upon exercise, conversion or exchange of any outstanding securities exercisable, convertible or exchangeable into or for shares of common stock of the Target including,
without limitation, all outstanding stock options of the Target. For purposes of this Section 10(b), consideration includes cash, securities, property, rights (contractual or otherwise), any dividends payable to stockholders of the
Target after the date hereof (other than normal, ordinary course, recurring dividends) and any other form of consideration. 

  
 -8-

 (c) For purposes of this Warrant, “Change of Control” means the occurrence
of any of the following: 
 (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”)) is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent
(50%) or more of the total voting power represented by the Company’s then-outstanding voting securities; 
 (ii) any
merger or consolidation of the Company with any other corporation that has been approved by the stockholders of the Company, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately
prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the total voting power represented by the voting securities of the
Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of complete liquidation of the Company; or 

(iii) any sale or disposition by the Company, in one transaction or a series of related transactions, of all or substantially all the
Company’s assets. 
 Section 11. Benefits. Nothing in this Warrant shall be construed to give any person, firm
or corporation (other than the Company and the Warrantholder) any legal or equitable right, remedy or claim, it being agreed that this Warrant shall be for the sole and exclusive benefit of the Company and the Warrantholder. 

Section 12. Notices to Warrantholder.
 (a) Upon the happening of any event requiring an adjustment of the Warrant Price, the Company shall promptly give written notice thereof to the Warrantholder, stating the adjusted Warrant Price and the
adjusted number of Warrant Shares resulting from such event and setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Failure to give such notice to the Warrantholder or any defect
therein shall not affect the legality or validity of the subject adjustment. 
 (b) The Company shall provide Warrantholder
written notice of any dividend or distribution on the Common Stock that is payable in cash or other assets (other than Common Stock) at least five (5) business days prior to the record date of such dividend or distribution. 

Section 13. Identity of Transfer Agent. The Transfer Agent for the Common Stock is BNY Mellon Shareowner
Services. Upon the appointment of any subsequent transfer agent for the Common Stock or other shares of the Company’s capital stock issuable upon the exercise of the rights of purchase represented by the Warrant, the Company will mail to
the Warrantholder a statement setting forth the name and address of such transfer agent. 
 Section 14.
Notices. Unless otherwise provided, any notice required or permitted under this Warrant shall be given in writing and shall be deemed effectively given as hereinafter described (a) if given by personal delivery, then such notice
shall be deemed given upon such delivery, (b) if given by facsimile, then such notice shall be deemed given upon receipt of 

  
 -9-

 
confirmation of complete transmittal, (c) if given by mail, then such notice shall be deemed given upon the earlier of (i) receipt of such notice by the recipient or (ii) three
days after such notice is deposited in first class mail, postage prepaid, and (d) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one day after delivery to such carrier. All notices
shall be addressed as follows: if to the Warrantholder, at its address as set forth in the Company’s books and records and, if to the Company, at the address as follows, or at such other address as the Warrantholder or the Company may designate
by ten days’ advance written notice to the other: 
 If to the Company: 

 

	
	 InfoSpace, Inc.

	 601 108th Avenue NE, Suite 1200

	 Bellevue, WA 98004-5840

	 Attention: General Counsel

	 Fax: 425.201.6167

 With a copy to: 
  

	
	 Perkins Coie LLP

	 1201 Third Avenue, Suite 4800

	 Seattle, WA 98101

	 Attention: Andrew Bor

	 Fax: 206.359.9577

 Section 15. Successors. All the covenants and provisions hereof by or for the benefit of
the Warrantholder shall bind and inure to the benefit of its respective successors and assigns hereunder. 
 Section 16.
Governing Law. This Warrant shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without reference to the choice of law provisions thereof. The Company and, by accepting this Warrant,
the Warrantholder, each irrevocably submits to the exclusive jurisdiction of the courts of the State of Washington located in King County and the United States District Court for the Western District of Washington for the purpose of any suit,
action, proceeding or judgment relating to or arising out of this Warrant and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the
world by the same methods as are specified for the giving of notices under this Warrant. The Company and, by accepting this Warrant, the Warrantholder, each irrevocably consents to the jurisdiction of any such court in any such suit, action or
proceeding and to the laying of venue in such court. The Company and, by accepting this Warrant, the Warrantholder, each irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and
irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 

  
 -10-

 Section 17. Cashless Exercise. If (a) the Common Stock is traded on Nasdaq
or another national securities exchange and (b) the Common Stock issuable upon exercise of this Warrant is not registered pursuant to a currently effective registration statement under the Securities Act and may not be sold pursuant to the last
sentence of Rule 144(b)(i) under the Securities Act, the Warrantholder may elect to receive, without the payment by the Warrantholder of the aggregate Warrant Price in respect of the shares of Common Stock to be acquired, shares of Common Stock
equal to the value of this Warrant or any portion hereof by the surrender of this Warrant (or such portion of this Warrant being so exercised) together with the Net Issue Election Notice annexed hereto as Appendix B duly executed, at the office of
the Company. Thereupon, the Company shall issue to the Warrantholder such number of fully paid, validly issued and nonassessable shares of Common Stock as is computed using the following formula: 

 

					
	X =	 	 Y (A - B)
	 	
		 	      A	 	

 where 
 X = the number of shares of Common Stock which the Warrantholder has then requested be issued to the Warrantholder; 
 Y = the total number of shares of Common Stock covered by this Warrant which the Warrantholder has surrendered at such time for cashless exercise (including both shares to be issued to the Warrantholder
and shares to be canceled as payment therefor); 
 A = the Market Price of one share of Common Stock as at the time the net
issue election is made; and 
 B = the Warrant Price in effect under this Warrant at the time the net issue election is made.

 For these purposes, “Market Price” means the average of the consolidated closing bid price of the Common
Stock as reported on the NASDAQ Global Select Market (or such other national securities exchange on which the Common Stock is then traded) for the 15 consecutive trading days preceding the date on which the Warrantholder delivers the Net Issue
Election Notice pursuant to this Section 17. 
 Section 18. No Rights as Stockholder. Prior to the
exercise of this Warrant, the Warrantholder shall not have or exercise any rights as a stockholder of the Company by virtue of its ownership of this Warrant, nor shall anything contained herein be construed to confer upon the Warrantholder any of
the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any
recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until the Warrant
shall have been duly exercised and the Common Stock purchasable upon the exercise hereof shall have become deliverable, as provided herein. 

  
 -11-

 Section 19. Amendment; Waiver. Any term of this Warrant may be amended or
waived (including the adjustment provisions included in Section 8 of this Warrant) upon the written consent of the Company and the Warrantholder. 
 Section 20. Section Headings. The section headings in this Warrant are for the convenience of the Company and the Warrantholder and in no way alter, modify, amend, limit or restrict the
provisions hereof. 
 [signature page follows] 

  
 -12-

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed, as of
the 23rd day of August, 2011. 
  

			
	INFOSPACE, INC.
		
	 By:    
	 	/s/ William Ruckelshaus
	 Name: William Ruckelshaus

	 Title:    CEO and President

 Signature Page to Warrant 

 APPENDIX A 
 INFOSPACE, INC. 
 WARRANT EXERCISE FORM 

To: INFOSPACE, INC.: 
 The
undersigned hereby irrevocably elects to exercise the right of purchase represented by the within Warrant (“Warrant”) for, and to purchase thereunder by the payment of the Warrant Price and surrender of the Warrant,
             shares of Common Stock (“Warrant Shares”) provided for therein, and requests that certificates for the Warrant Shares be issued as follows: 

 

			
		 	  

		 	Name
		 	  

		 	Address
		 	  

		 	Federal Tax ID or Social Security No.

 and delivered by certified mail to the above address, 

and, if the number of Warrant Shares shall not be all the Warrant Shares purchasable upon exercise of the Warrant, that a new Warrant for the balance of
the Warrant Shares purchasable upon exercise of this Warrant be registered in the name of the undersigned Warrantholder or the undersigned’s Assignee as below indicated and delivered to the address stated below. 

The undersigned hereby affirms that the representations and warranties set forth in Section 5 of the Purchase Agreement (as defined in the Warrant)
are true and correct with respect to the undersigned as of the date hereof. 
  

			
	Dated:                        ,   
     	  	  

	  
 Note: The signature must correspond with the name
of the registered holder as written on the first page of the Warrant in every particular, without alteration or enlargement
 or any change whatever, unless the Warrant has been assigned.
	  	Signature
	  	
	  	  

	  	Name (please print)
	  	
	  	  

	  	  

		  	Address
		  	  

		  	 Federal Identification or

Social Security No.

		  	
		  	Assignee:
		  	  

 Appendix A to Warrant 

 APPENDIX B 
 Net Issue Election Notice 
 To: INFOSPACE, INC. 

Date: 
 The undersigned hereby
elects under Section 17 of this Warrant to surrender the right to purchase              shares of Common Stock pursuant to this Warrant and hereby requests the issuance of
             shares of Common Stock. The undersigned hereby affirms that the representations and warranties set forth in Section 5 of the Purchase Agreement (as defined in the
Warrant) are true and correct with respect to the undersigned as of the date hereof. The certificate(s) for the shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated below. 

 

			
		 	  

		 	Signature
		 	  

		 	Name for Registration
		 	  

		 	Mailing Address

 Appendix B to Warrant

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]